Sarepta Therapeutics (SRPT) Tops Q4 EPS by 23c

Sarepta Therapeutics (NASDAQ: SRPT) reported Q4 EPS of ($1.24), $0.23 better than the analyst estimate of ($1.47). Revenue for the quarter came in at $258.4 million versus the consensus estimate of $250.4 million.

For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• La-Z-Boy (LZB) Misses Q1 EPS by 6c, Misses on Revenue; Offers Weak Q2 Revenue Guidance
• Sypris Solutions (SYPR) Reports Q2 Loss of $0.14